首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2078890

憂鬱症治療市場：依藥物類型、適應症、通路和地區分類

Depression Therapeutics Market, By Drug Type, By Indication, By Distribution Channel, and By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，憂鬱症藥物市場規模將達到147.5億美元，到2033年將達到203.5億美元。預計從2026年到2033年，該市場將以4.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	147.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.70%	2033年市場規模預測：	203.5億美元

在世界許多地區，尤其是在都市區，憂鬱症正逐漸成為一種「隱形殺手」。憂鬱症的盛行率持續快速上升，其死亡率和發病率也顯著升高，因此醫療保健產業不斷研發新的藥物和療法。抗憂鬱症被用於治療多種精神疾病，從輕度到重度，包括重度憂鬱症和焦慮症。由於針對這些疾病的替代藥物療法有限，抗憂鬱症市場盈利豐厚。製藥公司正透過推出創新療法，例如選擇性血清素再回收抑制劑（SSRIs）和選擇性去甲腎上腺素再回收抑制劑（SNRIs），進一步推動抗憂鬱症領域的發展。憂鬱症是最常見的精神疾病之一，主要治療方法是服用抗憂鬱症。根據英國國家醫療服務體系數位部門（NHS Digital）的數據顯示，2016年抗憂鬱症處方量增加最多。

市場動態

全球憂鬱症市場受多種因素驅動，例如缺乏替代療法以及學名藥生產商的強大影響力。隨著許多主要藥物的專利保護到期，學名藥生產商正不斷開發產品變體，從而推動市場成長。這些藥物在改善治療效果方面的顯著療效，以及憂鬱症疾病盛行率的不斷上升，進一步促進了市場成長。

例如，艾爾建公司生產的 Fetzima 受三項專利保護，預計分別於 2031 年、2033 年和 2023 年到期。

然而，正如包裝上的黑框警告所表明的那樣，這些藥物相關的危及生命的副作用，以及主要公司缺乏研發，預計將阻礙憂鬱症市場的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球抗憂鬱症市場的主要參與者進行了分析：公司概況、財務績效、產品系列、市場佔有率、分銷策略、主要發展、策略和未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「全球抗憂鬱症市場報告」旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球抗憂鬱症市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Johnson & Johnson
- GlaxoSmithKline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Eli Lilly and Company
- Sanofi SA
- Pfizer, Inc.
- Allergan plc.
- H. Lundbeck A/S
- Alkermes
- Allergan
- Novartis AG
- Biogen
- Sage Therapeutics, Inc.
- AbbVie Inc.

第9章

參考
調查方法

簡介目錄

Product Code: CMI1307

Depression Therapeutics Market is estimated to be valued at USD 14.75 Bn in 2026 and is expected to reach USD 20.35 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 14.75 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.70%	2033 Value Projection:	USD 20.35 Bn

Depression has emerged as a 'silent killer' in several regions across the world, particularly in urban cities. The prevalence of depression continues to grow rapidly with considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit of novel medications and therapies. Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for the treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescription observed the largest increase in 2016.

Market Dynamics

The global depression drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, which in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market.

For instance, Fetzima, manufactured by Allergan Plc., is protected by three patents, which are expected to expire in 2031, 2033, and 2023.

However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression drugs market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global depression drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson & Johnson, Sanofi S.A., Pfizer, Inc., Allergan plc, H. Lundbeck A/S, and Alkermes
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global depression drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression drugs market

Detailed Segmentation:

Global Depression Drugs Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
Antipsychotics
Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
Global Depression Drugs Market, By Indication:
Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others
Global Depression Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Depression Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Drug Type
  - Antidepressants
  - Antipsychotics
  - Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- By Indication
  - Major Depressive Disorder (MDD)
  - Bipolar Disorder
  - Dysthymic Disorder
  - Postpartum Depression
  - Seasonal Affective Disorder (SAD)
  - Premenstrual Dysphoric Disorder (PMDD)
  - Others
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Merck & Co., Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
GlaxoSmithKline plc
AstraZeneca Plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Johnson & Johnson
Sanofi S.A.
Pfizer, Inc.
Allergan plc
Lundbeck A/S
Alkermes

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Pipeline Analysis
Distribution Landscape
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Depression Therapeutics Market, By Drug Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
  - Selective Serotonin Reuptake Inhibitors (SSRIs)
  - Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  - Serotonin Modulators
  - Tricyclic & Tetracyclic Antidepressants
  - Atypical Antidepressants
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Depression Therapeutics Market, By Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Depression Therapeutics Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Depression Therapeutics Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Johnson & Johnson
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GlaxoSmithKline plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Limited.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Allergan plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- H. Lundbeck A/S
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alkermes
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Allergan
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biogen
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sage Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies